Aldeyra Therapeutics, Inc. $ALDX

What the company doesAI summary of filing

Aldeyra Therapeutics is a clinical-stage biotechnology company developing small-molecule pharmaceuticals targeting reactive aldehyde species (RASP) and methotrexate formulations for immune-mediated diseases. The company's lead candidate, reproxalap, is a topical RASP modulator in late-stage development for dry eye disease and allergic conjunctivitis; it has not yet received FDA approval but has a resubmitted New Drug Application with an expected FDA decision in March 2026. The company also develops ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa, along with earlier-stage RASP modulators ADX-248 and ADX-246 for systemic inflammatory diseases. Aldeyra is pre-revenue and has funded operations through equity and debt financing; it has granted AbbVie an exclusive option to co-license reproxalap in the United States and exclusively license it outside the United States, with potential milestone payments and profit-sharing if the option is exercised. [10-K 2026-02-27]

Segments: Reproxalap (RASP modulator for dry eye disease and allergic conjunctivitis), ADX-2191 (intravitreal methotrexate for vitreoretinal lymphoma and retinitis pigmentosa), ADX-248 (oral RASP modulator for systemic inflammation), ADX-246 (intravitreal RASP modulator for age-related macular degeneration)